Main findings
Our study demonstrates that Veregen®, a topical EGCG ointment, is not
only safe but potentially effective in the treatment of uVIN. All
patients in the Veregen® treatment arm showed at least a partial
clinical response with only 2 patients showing disease progression and
recurrence, respectively, at 52 weeks follow up. Results from DLQI and
McGills pain scores suggest a trend towards symptom improvements
following Veregen® treatment when compare to baseline and placebo, thus,
implicating that topical application of EGCG treatment offers symptoms
relieve in these patients. Although approximately 30% of patients in
the Veregen® group did not adhere to treatment protocol and had to
reduce treatment dose or prematurely stop treatment, the side effects
profiles were reasonably good with the majority of patients experiencing
grade 1 or 2 toxicity in the form of localised irritation. When compared
to baseline or pre-treatment, many patients already had underlying
symptoms of local irritation, and Veregen® treatment per se did
not worsen their symptoms substantially. Moreover, all the adverse
effects reported by patients were fully reversible upon stopping
Veregen® treatment.